Real-world evidence of constipation and laxative use in the Korean population with chronic kidney disease from a common data model

Kipyo Kim,Ji-Eun Kim,Jae Ho Kim,Seong Hee Ahn,Chai Young Jung,Seun Deuk Hwang,Seoung Woo Lee,Joon Ho Song
DOI: https://doi.org/10.1038/s41598-024-57382-7
IF: 4.6
2024-03-20
Scientific Reports
Abstract:Constipation is a highly prevalent gastrointestinal disorder in patients with chronic kidney disease (CKD). However, our understanding of its epidemiology and management in CKD is limited. We aimed to explore real-world data on constipation and laxative use in patients with CKD in a nationwide population-based cohort from the Korean Health Insurance Review and Assessment-National Patient Sample database. This study analyzed retrospective health claims data in Korea from 2012 to 2017 that were transformed into the Observational Medical Outcomes Partnership Common Data Model. The pooled proportion of constipation diagnoses was 30.5% in all patients with CKD and 15.9%, 16.5%, 17.4%, 29.9%, and 43.3% in patients with CKD stages 1–5, respectively, suggesting a higher prevalence in advanced CKD. Patients receiving peritoneal dialysis or hemodialysis had the highest prevalence of constipation, while transplant recipients showed a prevalence comparable to that of patients with early CKD. Patients with CKD had a significantly higher risk of constipation than age- and sex-matched non-CKD individuals (range of odds ratio [OR]:1.66–1.90). Laxative prescribing patterns differed by CKD severity. Osmotic agents were prescribed in more than half of patients with advanced CKD, while magnesium salts and bulking agents were prescribed less frequently. The CKD patients with constipation were more likely to be prescribed constipation-inducing medications, including antipsychotic and neurological medications. Our findings provide real-world constipation and laxative prescription status in the Korean CKD population, revealing a significantly higher risk of constipation and different laxative prescribing patterns in patients with CKD.
multidisciplinary sciences
What problem does this paper attempt to address?
The problem that this paper attempts to solve is the real - world evidence of constipation and the use of its treatment drugs in patients with chronic kidney disease (CKD). Specifically, the study aims to: 1. **Explore the prevalence of constipation in CKD patients**: The study analyzed retrospective health claim data based on the Health Insurance Review and Assessment (HIRA) - National Patient Sample Database nationwide in South Korea. Data from 2012 to 2017 were converted into the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). The study found that the proportion of constipation diagnosis in CKD patients was 30.5%, and as the CKD stage progressed, the prevalence of constipation increased significantly, especially in patients with advanced CKD. 2. **Evaluate the risk of constipation in CKD patients**: Through logistic regression analysis, the study compared the risk of constipation between CKD patients and non - CKD individuals matched by age and gender. The results showed that the risk of constipation in CKD patients was significantly higher than that in non - CKD individuals, with an odds ratio (OR) ranging from 1.66 to 1.90. 3. **Analyze the laxative use patterns in CKD patients**: The study found that there were differences in laxative use among patients at different CKD stages. For example, osmotic laxatives (such as lactulose) were most frequently used in patients with advanced CKD, while the use frequencies of magnesium salts and bulking agents were lower. In addition, among patients receiving peritoneal dialysis (PD) or hemodialysis (HD), the prevalence of constipation was the highest, while the prevalence of constipation in transplant recipients was similar to that in patients with early CKD. 4. **Explore the prescription differences of constipation - related drugs**: The study also evaluated the prescription differences of constipation - related drugs in CKD patients. The results indicated that CKD patients with constipation were more often prescribed drugs that may cause constipation, such as antipsychotics and neurological drugs. Through these analyses, the study provides real - world evidence of constipation and its treatment in CKD patients, revealing the high risk of constipation in CKD patients and the laxative use patterns at different CKD stages. These findings are helpful for improving constipation management and enhancing the quality of life in CKD patients.